Pear Therapeutics, Inc. (NASDAQ:PEAR – Get Rating) saw a significant decrease in short interest during the month of May. As of May 31st, there was short interest totalling 1,150,000 shares, a decrease of 19.6% from the May 15th total of 1,430,000 shares. Based on an average daily volume of 319,800 shares, the days-to-cover ratio is […]
EQRx (NASDAQ:EQRX – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. The firm presently has a $4.75 price target on the stock. Zacks Investment Research‘s price target points to a potential upside of 10.47% […]
Wall Street brokerages predict that Pear Therapeutics, Inc. (NASDAQ:PEAR – Get Rating) will post ($0.25) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Pear Therapeutics’ earnings. The company is expected to announce its next earnings results on Monday, January 1st. According to Zacks, […]
Pear Therapeutics (NASDAQ:PEAR – Get Rating) had its target price decreased by stock analysts at Chardan Capital from $16.00 to $13.00 in a report released on Tuesday, The Fly reports. Chardan Capital’s target price indicates a potential upside of 262.12% from the company’s previous close. PEAR has been the subject of a number of other […]